Deep multi-view contrastive learning for cancer subtype identification

Wenlan Chen1, Hong Wang1, Cheng Liang1

  • 1School of Information Science and Engineering, Shandong Normal University, Jinan, 250358, China.

PubMed

Insights

Deep Multi-view Contrastive Learning (DMCL) effectively identifies cancer subtypes from multi-omics data. This approach aids in developing precise cancer therapies by revealing distinct molecular profiles and potential drug responses.

Area of Science:

  • Computational biology
  • Bioinformatics
  • Machine learning in oncology

Background:

  • Cancer heterogeneity presents significant challenges for developing precise therapeutic strategies.
  • Identifying distinct cancer subtypes based on molecular profiles is crucial for effective clinical treatments.
  • Integrating multi-omics datasets for cancer subtype identification requires advanced computational methods.

Purpose of the Study:

  • To propose a novel self-supervised learning model, Deep Multi-view Contrastive Learning (DMCL), for accurate cancer subtype identification.
  • To develop an end-to-end framework that integrates reconstruction, contrastive, and clustering losses for feature representation and cluster preservation.
  • To demonstrate the capability of DMCL in directly outputting cancer subtypes.

Main Methods:

  • Developed Deep Multi-view Contrastive Learning (DMCL), a self-supervised learning model.
  • Incorporated reconstruction loss, contrastive loss, and clustering loss into a unified framework.
  • Evaluated DMCL on 10 cancer multi-omics datasets and one integrated dataset, comparing against eight alternative methods.

Main Results:

  • DMCL demonstrated superior performance compared to existing methods in cancer subtype identification across multiple datasets.
  • The model effectively encodes sample discriminative information and preserves cluster structures in embedded feature representations.
  • A case study on liver cancer indicated that identified subtypes may exhibit differential responses to chemotherapeutic drugs.

Conclusions:

  • DMCL offers a powerful and efficient computational method for integrating multi-omics data for cancer subtype identification.
  • The findings suggest DMCL's potential to guide personalized cancer treatment strategies by revealing subtype-specific drug sensitivities.
  • This approach advances the field of precision oncology through improved subtype discovery from complex molecular data.